Literature DB >> 19058325

Mouse models in liver cancer research: a review of current literature.

Martijn W H Leenders1, Maarten W Nijkamp, Inne H M Borel Rinkes.   

Abstract

Primary liver cancer remains one of the most lethal malignancies worldwide. Due to differences in prevalence of etiological factors the incidence of primary liver cancer varies among the world, with a peak in East-Asia. As this disease is still lethal in most of the cases, research has to be done to improve our understanding of the disease, offering insights for possible treatment options. For this purpose, animal models are widely used, especially mouse models. In this review, we describe the different types of mouse models used in liver cancer research, with emphasis on genetically engineered mice used in this field. We focus on hepatocellular carcinoma (HCC), as this is by far the most common type of primary liver cancer, accounting for 70%-85% of cases.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19058325      PMCID: PMC2773853          DOI: 10.3748/wjg.14.6915

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  79 in total

1.  Hepatitis B injury, male gender, aflatoxin, and p53 expression each contribute to hepatocarcinogenesis in transgenic mice.

Authors:  N Ghebranious; S Sell
Journal:  Hepatology       Date:  1998-02       Impact factor: 17.425

Review 2.  Multistep hepatocarcinogenesis in transgenic mice harboring SV40 T-antigen gene.

Authors:  T Kitagawa; O Hino; G H Lee; H Li; J Liu; K Nomura; K Ohtake; Y Furuta; S Aizawa
Journal:  Princess Takamatsu Symp       Date:  1991

3.  Incidence of hepatocellular carcinoma in transgenic mice expressing the hepatitis B virus X-protein.

Authors:  D Y Yu; H B Moon; J K Son; S Jeong; S L Yu; H Yoon; Y M Han; C S Lee; J S Park; C H Lee; B H Hyun; S Murakami; K K Lee
Journal:  J Hepatol       Date:  1999-07       Impact factor: 25.083

Review 4.  Hepatitis B virus (HBV)-transgenic mice as an investigative tool to study immunopathology during HBV infection.

Authors:  S K Akbar; M Onji
Journal:  Int J Exp Pathol       Date:  1998-10       Impact factor: 1.925

5.  The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice.

Authors:  K Moriya; H Fujie; Y Shintani; H Yotsuyanagi; T Tsutsumi; K Ishibashi; Y Matsuura; S Kimura; T Miyamura; K Koike
Journal:  Nat Med       Date:  1998-09       Impact factor: 53.440

Review 6.  Epidemiological characteristics and risk factors of hepatocellular carcinoma.

Authors:  C J Chen; M W Yu; Y F Liaw
Journal:  J Gastroenterol Hepatol       Date:  1997-10       Impact factor: 4.029

7.  Liver-targeted disruption of Apc in mice activates beta-catenin signaling and leads to hepatocellular carcinomas.

Authors:  S Colnot; T Decaens; M Niwa-Kawakita; C Godard; G Hamard; A Kahn; M Giovannini; C Perret
Journal:  Proc Natl Acad Sci U S A       Date:  2004-11-24       Impact factor: 11.205

8.  Transgenic mouse model for synergistic effects of nuclear oncogenes and growth factors in tumorigenesis: interaction of c-myc and transforming growth factor alpha in hepatic oncogenesis.

Authors:  H Murakami; N D Sanderson; P Nagy; P A Marino; G Merlino; S S Thorgeirsson
Journal:  Cancer Res       Date:  1993-04-15       Impact factor: 12.701

9.  Development of liver tumors in transforming growth factor alpha transgenic mice.

Authors:  G H Lee; G Merlino; N Fausto
Journal:  Cancer Res       Date:  1992-10-01       Impact factor: 12.701

View more
  22 in total

1.  A murine model for non-alcoholic steatohepatitis showing evidence of association between diabetes and hepatocellular carcinoma.

Authors:  Masato Fujii; Yuichiro Shibazaki; Kyoko Wakamatsu; Yutaka Honda; Yusuke Kawauchi; Kenji Suzuki; Somasundaram Arumugam; Kenichi Watanabe; Takafumi Ichida; Hitoshi Asakura; Hiroyuki Yoneyama
Journal:  Med Mol Morphol       Date:  2013-02-22       Impact factor: 2.309

2.  Polyploid Hepatocytes Facilitate Adaptation and Regeneration to Chronic Liver Injury.

Authors:  Patrick D Wilkinson; Frances Alencastro; Evan R Delgado; Madeleine P Leek; Matthew P Weirich; P Anthony Otero; Nairita Roy; Whitney K Brown; Michael Oertel; Andrew W Duncan
Journal:  Am J Pathol       Date:  2019-03-28       Impact factor: 4.307

Review 3.  Viral hepatocarcinogenesis.

Authors:  W-L Tsai; R T Chung
Journal:  Oncogene       Date:  2010-03-15       Impact factor: 9.867

Review 4.  Intracellular signaling and hepatocellular carcinoma.

Authors:  Polina Iakova; Lubov Timchenko; Nikolai A Timchenko
Journal:  Semin Cancer Biol       Date:  2010-09-17       Impact factor: 15.707

Review 5.  Alpha-fetoprotein-targeted reporter gene expression imaging in hepatocellular carcinoma.

Authors:  Kwang Il Kim; Hye Kyung Chung; Ju Hui Park; Yong Jin Lee; Joo Hyun Kang
Journal:  World J Gastroenterol       Date:  2016-07-21       Impact factor: 5.742

6.  Novel murine tumour models depend on strain and route of inoculation.

Authors:  Qiang Fu; Andrew Satterlee; Yongjun Wang; Yuhua Wang; Dun Wang; Jingling Tang; Zhonggui He; Feng Liu
Journal:  Int J Exp Pathol       Date:  2016-07-28       Impact factor: 1.925

Review 7.  Inflammation- and stress-related signaling pathways in hepatocarcinogenesis.

Authors:  Hayato Nakagawa; Shin Maeda
Journal:  World J Gastroenterol       Date:  2012-08-21       Impact factor: 5.742

Review 8.  Experimental models of hepatocellular carcinoma: developments and evolution.

Authors:  Long Wu; Zhao-You Tang; Yan Li
Journal:  J Cancer Res Clin Oncol       Date:  2009-04-28       Impact factor: 4.553

9.  HRAS, EGFR, MET, and RON Genes Are Recurrently Activated by Provirus Insertion in Liver Tumors Induced by the Retrovirus Myeloblastosis-Associated Virus 2.

Authors:  Vladimir Pecenka; Petr Pajer; Vít Karafiat; Petra Kasparova; Jana Dudlova; Michal Dvorak
Journal:  J Virol       Date:  2017-09-27       Impact factor: 5.103

Review 10.  Progress in stem cell-derived technologies for hepatocellular carcinoma.

Authors:  Rajagopal N Aravalli
Journal:  Stem Cells Cloning       Date:  2010-05-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.